July 31, 2026
Drug Recalls - Availability
Baxter – Recall of cefazolin injection
July 24, 2026 - Baxter announced a voluntary, consumer level recall of one lot of cefazolin in dextrose injection due to a report of particulate matter found in the solution identified as cardboard.
Drug Recalls - Availability
Sunny PharmTech – Recall of cyclophosphamide injection
July 24, 2026 - Sunny Pharmtech announced a voluntary, consumer level recall of three lots of cyclophosphamide for injection, 1g/vial and 2g/vial due to the presence of particulate matter identified as steel.
Drug Recalls - Availability
American Regent – Recall of papaverine injection
July 27, 2026 - The FDA posted American Regent’s voluntary, consumer level recall of one lot of papaverine hydrochloride injection 60 mg/2 mL due to the presence of particulate matter identified as glass and/or paraformaldehyde.l.
Drug Approvals
Furoscix® ReadyFlow™ (furosemide) – New formulation approval
July 24, 2026 - MannKind announced the FDA approval of Furoscix ReadyFlow (furosemide), for the treatment of edema in adult patients with chronic heart failure (CHF) or chronic kidney disease (CKD), including the nephrotic syndrome.
Drug Approvals
Garzulys™ (insulin aspart-fsan) – New biosimilar approval
July 24, 2026 - The FDA approved Meitheal’s Garzulys (insulin aspart-fsan), biosimilar to Novo Nordisk’s Novolog® (insulin aspart).
Drug Approvals
Jideytro™ (zidesamtinib) – New orphan drug approval
July 22, 2026 - GSK announced the FDA approval of Jideytro (zidesamtinib), for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received a prior ROS1 kinase inhibitor.
Drug Approvals
Lytenava™ (bevacizumab-vikg) – New drug approval
July 24, 2026 - Outlook Therapeutics announced the FDA approval of Lytenava (bevacizumab-vikg), for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).
Drug Approvals
Simtriyo® (centanafadine) – New drug approval
July 24, 2026 - Otsuka announced the FDA approval of Simtriyo (centanafadine), for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older weighing at least 20 kg.
New Generics
Janumet® XR (sitagliptin/metformin) – First-time generic
July 24, 2026 - Par Health launched an AB-rated generic version of Merck’s Janumet XR (sitagliptin/metformin) extended-release tablets.
Clinical Updates
Rezzayo™ (rezafungin) – Expanded indication
July 16, 2026 - The FDA approved Melinta Therapeutics’ Rezzayo (rezafungin), in adults and pediatric patients 12 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.